No. of unnecessary antibiotic prescriptions
No. of unnecessary antibiotic prescriptions
Company
Overview
Team
Awards
Careers
Contact Us
What's New
Products
MeMed BV
MeMed Key
MeMed COVID-19 Severity
Pipeline
Evidence
Publications & Conferences
Support
Document Library
Instructional Videos Key 1.1
Instructional Videos Key 1.2
Instructional Videos COVID-19 Severity
Customer Support
AMR
The crisis of antibiotic misuse
Facts & Figures
The Resistant Bacteria Problem
The Diagnostic Gap
The Economic Impact
More
Use tab to navigate through the menu items.
News & Media
Media Coverage
Press Releases
Events
FDA Clearance News
Rapid test to distinguish bacterial and viral infections wins US approval
Full story
MeMed's test to help reduce the misuse of antibiotics has been approved by the FDA (Hebrew)
Full story
MeMed’s Diagnostics, BV Test and Key Platform Get 510(k) Clearance
Full story
FDA Clears New Technology to Differentiate Bacterial, Viral Infections Using Biomarkers
Full story
Bacterial and Viral Biomarker Test Gains US FDA Clearance
Full story
MeMed Received FDA Clearance for Infection Test
Full story
Platform distinguishing between viral and bacterial infections cleared by FDA
Full story
US approves MeMed test to distinguish bacterial from viral infections
Full story
MeMed Gets FDA 510(k) Clearance for Test Distinguishing Between Viral, Bacterial Infections
Full story
FDA clears MeMed’s point-of-care infectious disease test
Full story
Israel’s MeMed gets FDA approval for ‘breakthrough’ infection test
Full story
After a decade and 130 million dollars, the MeMed test receives FDA clearance
Full story
COVID-19 Severity News
COVID-19 Severity test is approved for sale in the UK
Full story
MeMed’s Covid-19 severity test receives its CE Mark to predict severe outcomes
Full story
Pioneering test which can indicate COVID-19 severity receives
CE Mark
Full story
Test predicting COVID-19 severity receives CE mark
Full story
Israeli Startups Join The Fight Against Coronavirus
Full story
MeMed's co-founder and CEO, Dr. Eran Eden on the BioBoss Podcast
Full story
OurCrowd Portfolio Companies Pivot to Tackle Coronavirus Pandemic
Full story
MeMed to predict which COVID-19 patients will worsen
Full story
Media Coverage
Israeli firm advances diagnostic solutions for Covid-19
Full story
MeMed Receives CE Mark for Diagnostic Platform & Infection Assay
Full story
Test aiming to provide better treatment decisions receives
CE mark
Full story
MeMed Ramping Up Commercialization Efforts Following Regulatory Approvals
Full story
MeMed Receives CE for Advanced Diagnostic Test
Full story
MeMed secures CE mark for new point of need blood test
Full story
MeMed Receives CE-IVD Mark for Infectious Disease Test
Full story
MeMed Receives Regulatory Green Light for Test
Full story
ISRAEL21C: Israel races to find solutions for coronavirus
Full story
Interview with Eran Eden, MeMed's CEO
Full story
MeMed Named "Technology Pioneer" by World Economic Forum
Full story
Study: MeMed's blood test distinguishes between bacterial, viral infections in children
Full story
US DoD Commits Additional Funds to MeMed's Innovative Bacterial Versus Viral Test
Full story
Frost & Sullivan Recognizes MeMed with European Technology Leadership Award
Full story
The journey towards a disruptive blood test that can help address the threat of antibiotic resistance
Full story
Rapid blood test to 'cut antibiotic use'
Full story
MeMed raises $70M for immune system-based infection diagnostics
Full story
Israeli Firm, US Department Of Defense To Fight Infectious Disease Together
Full story
MeMed Publishes New Data on Infectious Disease Dx, Plans 2018 Launch of POC Test
Full story
MeMed swiftly diagnoses if a disease is viral or bacterial
Full story
Towards a world without antibiotics
Full story
(Hebrew)
MeMed raises $70M
Full story
New study shows MeMed's blood test accurately distinguishes bacterial and viral infections
Full story
Novel Assay Distinguishes Bacterial From Viral Infection in Kids
Full story
Infectious Disease Detective
Full story
MeMed Using $70M Funding Round to Develop Infection Test and POC Platform
Full story
The ultimate goal is to right-size antibiotic use
Full story
Israeli infection diagnostic start-up wins $9.2M funding boost
Full story
MeMed has received a contract from the Defense Threat Reduction Agency
Full story
MeMed Wins $4.1M DOD Grant toward Manufacturing of POC Platform
Full story
Viruses from Mars, bacteria from Venus
Podcast
(Hebrew)
MeMed Wins $9.2M DTRA Contract for PoC IVD to Reduce Antibiotic Misuse
Full story
MeMed Rolling Out Proteomic Test to Distinguish Between Bacterial, Viral Infections
Full story
A new blood test could stop doctors from over prescribing antibiotics
Full story
New Study Shows Superiority of MeMed's ImmunoXpert™ Over Procalcitonin, CRP, and HNL
Full story
MeMed has a rapid diagnostic that could help revolutionize the fight against drug-resistant bacteria
Full story
Press Releases
Fierce Medtech names MeMed as one of its ‘Fierce 15’ medical technology companies
March 7, 2022
MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio
January 10, 2022
Clinical Data Published in
Clinical Microbiology and Infection
Support Use of MeMed’s Test in Reducing Antibiotic Overuse in Children
December 1st, 2021
Diasorin launches Liaison® MeMed BV®, the first high throughput blood test to differentiate between bacterial and viral infections, in countries accepting the CE Mark
November 23rd, 2021
FDA Clears First Technology to Distinguish between Bacterial and Viral Infections Using the Body’s Immune Response – The MeMed BV Test and MeMed Key Platform
September 20th, 2021
MeMed Named a Finalist for AACC’s Disruptive Technology Award for
MeMed COVID-19 Severity™ Test
August 5th, 2021
MeMed’s COVID-19 Severity Test Receives CE Mark for Predicting Severe Outcomes in
COVID-19 Patients
July 27, 2021
MeMed Key® Wins Red Dot Award for High Design Quality
April 21, 2021
Tanya Gottlieb, VP Scientific Affairs at MeMed, Appointed to the Board of the AMR Industry Alliance
April 19, 2021
MeMed and 360Dx Bring Together International Experts for a Timely Discussion on Predicting COVID-19 Severity Using the Host Immune Response
April 14, 2021
Riwat Lim Joins MeMed Team as Head of Commercial, Europe
January 19, 2021
Troy Boutelle Joins MeMed as Vice President of Commercial in North America and General Manager, U.S.
January 11, 2021
MeMed Appoints Industry Veteran Chris Hibberd to its Board of Directors
December 16, 2020
DiaSorin and MeMed Partner to Develop and Commercialize Novel Host Immune Response Based Diagnostic Solution
September 8, 2020
Prospective Study Finds Potential Utility of MeMed's Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients
July 23, 2020
MeMed Receives CE Mark for Two Pioneering Technologies: The MeMed BV™ Test and MeMed Key™ Point-of-Need Platform
June 2, 2020
MeMed Advances Diagnostic Solutions for COVID-19 Pandemic to Enable Enhanced Patient Management
Oct 29, 2019
News
Diagnostics Industry Veteran Dr. Frédéric Sweeney Joins MeMed as Chief Business Development Officer
May 25, 2020
MeMed to predict which COVID-19 patients will worsen
March 29, 2020
Israeli Startups Join The Fight Against Coronavirus
March 25, 2020
Meet the Israeli Tech Companies Fighting COVID-19 Head-On
March 25, 2020
OurCrowd Portfolio Companies Pivot to Tackle Coronavirus Pandemic
March 18, 2020
Events
Society of Critical Care Medicine
Feb 6 - 9 | San Juan, PR
European Society of Paediatric Infectious Diseases
May 9 - 13 | Athens, Greece
European Congress of Clinical Microbiology & Infectious Diseases
Apr 23 - 26 | Lisbon, Portugal
Миссия MeMed Diagnostics - преобразовать сложные сигналы иммунной системы в простые диагностические данные, которые изменят наши методы лечения инфекционных и воспалительных заболеваний - в нужном месте и в нужное время.